General Information of DTT (ID: TTUDR0C)

DTT Name Iron (Fe) DTT Info
Gene Name Fe

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deferiprone DMS2M7O Beta thalassemia 3A50.2 Approved [1]
Deferoxamine Mesylate DMTUKZH Acute iron or aluminum toxicity FB83.20 Approved [2]
Etidronate Disodium DMAWJIN Osteoporosis FB83.0 Approved [2]
Exjade DMHPRWG Iron overload disease 5C64.10 Approved [3]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Soluble ferric pyrophosphate DMLAYTP Iron-deficiency anemia 3A00 Phase 3 [4]
SPD602 DMKJ9LU Anemia 3A00-3A9Z Phase 2 [5]
DpC DM4ZDOE Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
Monohydroxyethylrutoside DMAQJHO Cardiovascular disease BA00-BE2Z Phase 1 [7]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
4 A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
5 ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
6 Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
7 Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.